Eutilex rallies on Japan trial buzz; Abion extends limit-up run[K-bio pulse]

작성일 07-01

<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
         <section dmcf-sid="yTVmyYA8SD">
          <div contents-hash="7f81e8402767bc83b4ec26697e7ddafd3e727ddd258cc010089d93e9fc0fe8ce" dmcf-pid="WxC9MeuSTE" dmcf-ptype="general">
           <div>
            This article was released as <strong>Pharm Edaily Premium Content</strong> on June 30, 2025, at 7:28 AM.
           </div>
          </div>
          <p contents-hash="72f36cd022042b14555e01c70f9cd413e496b793d57e4f1cb3c108098bbb7b86" dmcf-pid="YMh2Rd7vCk" dmcf-ptype="general">[Seungkwon Kim, Edaily Reporter] Shares of several Korean biopharmaceutical companies rocketed Friday after clinical-trial milestones and a high-value license-out agreement ignited buying across the sector.</p>
          <p contents-hash="d52fd3da12bb53f97e420d35f3dcdf17e7b4635b0e74368c37fb08e0b8a7ce6b" dmcf-pid="GRlVeJzTvc" dmcf-ptype="general"><strong> Key drivers behind Eutilex sudden surge</strong></p>
          <p contents-hash="2907da427da7a44dfd6a1d62e914062f28268786a50673e3937bae8e26a6d25b" dmcf-pid="HeSfdiqyWA" dmcf-ptype="general">Eutilex Co. hit its 30 percent daily trading limit, closing at 2,140 won, up 491 won, valuing the cell-therapy developer at 78.8 billion won ($58 million). Investors piled in ahead of an interim Phase 1 readout for its CAR-T therapy EU307, scheduled for next month at the Asia-Pacific Primary Liver Cancer Expert meeting (APPLE) in Kobe, Japan.</p>
          <p contents-hash="6cea023d98b4f85611c0b8dd8d5de924b5a643e0a2898de2901096cc8e1d702f" dmcf-pid="Xdv4JnBWSj" dmcf-ptype="general">PharmEdaily first reported the pending data release in a June 22 pay-to-read article titled “Eutilex’s Solid-Tumor CAR-T to Show Interim Data in Japan Next Month,” which was later distributed free on major portals. The report, traders said, helped fan anticipation of positive results.</p>
          <figure class="figure_frm origin_fig" contents-hash="bf787a31c595783b584f73b306efb4ba6e2ad2418d85d92d7f9cd46ba597af9d" dmcf-pid="ZJT8iLbYvN" dmcf-ptype="figure">
           <p class="link_figure"><img alt="Eutilex daily share-price trend (Data: KG Zeroin)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202507/01/Edaily/20250701092815349hrcw.jpg" data-org-width="510" dmcf-mid="Qmpgrse7lr" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202507/01/Edaily/20250701092815349hrcw.jpg" width="658"></p>
           <figcaption class="txt_caption default_figure">
            Eutilex daily share-price trend (Data: KG Zeroin)
           </figcaption>
          </figure>
          <div contents-hash="d36916de63531ac11ff030b42a6277c0e91bb7f1f8a23e1cf1d0e65d09e4863a" dmcf-pid="5iy6noKGla" dmcf-ptype="general">
           EU307 is designed to attack glypican-3, an antigen highly expressed on hepatocellular carcinoma cells but absent from healthy liver tissue. Unlike the six CAR-T therapies cleared by the U.S. Food and Drug Administration all for blood cancers EU307 aims to conquer the long-standing challenges of solid tumors.
          </div>
          <p contents-hash="b0ac23bcf5bda40dd13ab04ba9b853bc133c9d5ce065447e58cc94cc5b530b19" dmcf-pid="1IqcClLKyg" dmcf-ptype="general">Eutilex obtained Korean Phase 1 clearance in 2023 for an open-label study of up to 12 patients with relapsed or refractory liver cancer. About half the cohort has been dosed. Yonsei University’s Prof. Kim Do-young will present safety and early efficacy findings in Kobe, the company said.</p>
          <p contents-hash="a70b1dd9dd27f965b212922ee5360cfea72fdfba6da05b4a32e61bf3cc478822" dmcf-pid="tCBkhSo9To" dmcf-ptype="general">“APPLE will showcase EU307’s potential,” CEO Yoo Yeon-ho said, noting that Eutilex has strengthened its R&amp;D bench with industry-seasoned leaders.</p>
          <p contents-hash="e4eefe407710041cf57f109c9f298a3226c6887a4c8549cad2654755748c2b34" dmcf-pid="FhbElvg2SL" dmcf-ptype="general"><strong> Abion’s antibody deal electrifies trading</strong></p>
          <p contents-hash="9e96f4f91f3e729412a4473061fc043bbbae15c987c426729d26841d9653bfbb" dmcf-pid="3lKDSTaVSn" dmcf-ptype="general">Abion Co. also closed at its daily ceiling for a third straight session, ending 30 percent higher at 9,880 won. The oncology firm disclosed this week a license-out agreement for ABN501 an antibody targeting claudin-3 and four other proteins with an undisclosed partner.</p>
          <p contents-hash="aff7fa9b9c71bd67f9ec025673dbc60bca36ba8915ff301507c9e8787df6c500" dmcf-pid="0S9wvyNfvi" dmcf-ptype="general">Total deal value could reach $1.32 billion, including an upfront payment of $25 million and development milestones of up to $290 million. Commercial milestones may add another $1 billion.</p>
          <figure class="figure_frm origin_fig" contents-hash="89e4d143abf0b2cbe9027c7a1074b862e0058400f1c774079bfc88f5daa4ef1d" dmcf-pid="pv2rTWj4vJ" dmcf-ptype="figure">
           <p class="link_figure"><img alt="Abion weekly share-price trend (Data: KG Zeroin)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202507/01/Edaily/20250701092816750pgap.jpg" data-org-width="463" dmcf-mid="xEh2Rd7vyw" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202507/01/Edaily/20250701092816750pgap.jpg" width="658"></p>
           <figcaption class="txt_caption default_figure">
            Abion weekly share-price trend (Data: KG Zeroin)
           </figcaption>
          </figure>
          <div contents-hash="4e6bac03ba4287db4b58cebb1d0694b1b3ba1357cc02b5dfd57532736493d167" dmcf-pid="UTVmyYA8vd" dmcf-ptype="general">
           Molecular diagnostics company Genecurix Ltd. jumped 29.8 percent to 2,355 won after announcing a strategic partnership with German diagnostics heavyweight Qiagen. Genecurix will be the first official developer under Qiagen’s QIAcuityDxFour digital-PCR platform, extending its reach into global precision-medicine markets.
          </div>
          <p contents-hash="c88773c76858529308ce81e686dda22c2203e10e1b099461579453ce0d668296" dmcf-pid="uyfsWGc6Se" dmcf-ptype="general">“This partnership is a pivotal marker in Genecurix’s global expansion, following our recent commercialization pact in Japan with Hitachi High-Tech,” CEO Cho Sang-rae said, pledging further collaborations to drive growth.</p>
          <p contents-hash="2f95f7eb6379e189d0d6207ff294ba85073cc2e3f7cbfc8d284dfd8dbbed5093" dmcf-pid="7lWPLg9HCR" dmcf-ptype="general">김승권 (peace@edaily.co.kr) </p>
         </section> 
        </div> 
        <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>

이전

‘5세대 슈퍼루키’ 힛지스, 신곡 ‘CHARIZZMA’ 트레일러로 초고속 컴백 신호탄

07-01
다음

근력 강화 운동, 두세트만 해도 충분

07-01

등록된 댓글이 없습니다.

로그인한 회원만 댓글 등록이 가능합니다.

먹튀폴리스

Eutilex rallies on Japan trial buzz; Abion extends limit-up run[K-bio pulse]

멤버랭킹

관련자료

멤버랭킹